On February 29, 2024, Janux Therapeutics (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, announced the pricing of an underwritten public offering of 4,440,851 shares of its common stock at a public offering price of $46.50 per share and pre-funded warrants to purchase 1,935,483 shares of common stock at a price of $46.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Janux from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding the exercise of any pre-funded warrants, are expected to be approximately $296.5 million. In addition, Janux has granted the underwriters a 30-day option to purchase up to an additional 956,450 shares of its common stock. All of the shares to be sold in the offering are to be sold by Janux. The offering is expected to close on or about March 4, 2024, subject to customary closing conditions. Janux intends to use the net proceeds from the offering to advance clinical development of its internal product pipeline and for general corporate purposes.

Wilson Sonsini Goodrich & Rostai advised Janux Therapeutics on patent matters related to this transaction. The Wilson Sonsini team was led by Laurie McNamara and included Uale Taotafa, Michael Hostetler, Yingchun Ni, Rachna Ujwal, Shu Boboila, Sara Butterfield, Jacob Daniels, and Susan Jeong.

For more information, please see Janux's press release.